Nuvectis Pharma Inc (NASDAQ:NVCT) — Market Cap & Net Worth
Market Cap & Net Worth: Nuvectis Pharma Inc (NVCT)
Nuvectis Pharma Inc (NASDAQ:NVCT) has a market capitalization of $231.56 Million ($231.56 Million) as of June 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16057 globally and #3748 in its home market, demonstrating a 34.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvectis Pharma Inc's stock price $13.82 by its total outstanding shares 25614896 (25.61 Million). Review NVCT total liabilities to assess the company's total debt and financial obligations.
Nuvectis Pharma Inc Market Cap History: 2022 to 2026
Nuvectis Pharma Inc's market capitalization history from 2022 to 2026. Data shows growth from $192.11 Million to $354.00 Million (39.27% CAGR).
Index Memberships
Nuvectis Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #439 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #1570 of 3165 |
Weight: Nuvectis Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nuvectis Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvectis Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1289.34x
Nuvectis Pharma Inc's market cap is 1289.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $192.11 Million | $149.00K | -$18.79 Million | 1289.34x | N/A |
Competitor Companies of NVCT by Market Capitalization
Companies near Nuvectis Pharma Inc in the global market cap rankings as of June 20, 2026.
Key companies related to Nuvectis Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Nuvectis Pharma Inc Historical Marketcap From 2022 to 2026
Between 2022 and today, Nuvectis Pharma Inc's market cap moved from $192.11 Million to $ 354.00 Million, with a yearly change of 39.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $354.00 Million | +83.05% |
| 2025 | $193.39 Million | +39.56% |
| 2024 | $138.58 Million | -35.13% |
| 2023 | $213.63 Million | +11.20% |
| 2022 | $192.11 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Nuvectis Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $231.56 Million USD |
| MoneyControl | $231.56 Million USD |
| MarketWatch | $231.56 Million USD |
| marketcap.company | $231.56 Million USD |
| Reuters | $231.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also dev… Read more